- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02669069
Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)
September 26, 2022 updated by: Neuromod Devices Ltd.
This is a three arm, patient subtyping and parameter optimisation study for a neuromodulation treatment for tinnitus.
Study Overview
Detailed Description
Participants with chronic tinnitus will be provided with a CE marked neuromodulation device.
Devices will be programmed with one of 3 stimulation parameter settings.
After 12 weeks of use, differences in tinnitus severity scores will be compared between the 3 arms and within the arms for patient subtype analysis.
Study Type
Interventional
Enrollment (Actual)
326
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 70 years of age
- The ability to read and understand English/German
- Willing and able to provide informed consent
- Willing to commit to the full duration of the study
- Have been experiencing tinnitus 3 months to 5 years
- Experiencing subjective tinnitus
- Baseline Tinnitus Handicap Inventory (THI) score of 28 to 76 points
- Baseline Minimum Masking Level (MML) of 20 to 80 dBHL
- Maximum AC pure-tone audiometry hearing loss of 80 dB HL at any test frequency in the range of 2 to 8 kHz or of 40 dB HL in the range of 250 to 1000 Hz either unilaterally or bi-laterally
Exclusion Criteria:
- If participant has been diagnosed with objective tinnitus
- Commenced usage of hearing aid within the last 90 days
- Cases where pulsatility is the dominant feature of tinnitus
- Patients whose tinnitus cannot be masked during MML assessment
- Meniere's disease
- Significantly severe Loudness Discomfort Level (LDL), <30 dB SL
- Depression or neuro-psychological condition, previously diagnosed or identified from the State-Trait Anxiety Inventory (STAI) scores greater than 120
- Diagnosed with somatic tinnitus resulting from head or neck injury
- Temporomandibular Joint Disorder (TMJ)
- Current or previous involvement in medico-legal cases
- Pregnancy
- Oral piercings
- Neurological conditions that may lead to loss of consciousness (e.g. epilepsy) or is considered to be the dominant feature of the tinnitus, as assessed by audiologist or ENT consultant
- Severe cognitive impairment based on Mini Mental State Examination (MMSE), less than 20
- Pacemakers or other electro-active implanted devices
- Have used Neuromod Devices products in the past
- Participants currently prescribed drugs for a Central Nervous System pathology, i.e. epilepsy, Multiple Sclerosis (MS), Parkinson's, bi-polar disorder.
- The site Principal Investigator does not deem the candidate to be suitable for the study for other reasons not listed above
- Self-reporting episodes of Auditory hallucinations
- Abnormal Otoscopy as assessed by the Audiologist, including active Otitis Media, perforation and hearing loss that is identified as completely conductive
- Abnormal Tympanometry as assessed by the Audiologist
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PS1
|
Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss.
Electrical pulses in the somatosensory stimulation are synchronous with the tones.
|
Active Comparator: PS2
|
Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss.
Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
|
Active Comparator: PS3
|
Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss.
Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tinnitus Functional Index
Time Frame: Between baseline and 12 weeks
|
Between baseline and 12 weeks
|
Tinnitus Handicap Inventory
Time Frame: Between baseline and 12 weeks
|
Between baseline and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mr. Brendan Conlon, St. James's Hospital, Dublin
- Principal Investigator: Prof. Dr. med. Berthold Langguth, University of Regensburg
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 27, 2016
Primary Completion (Actual)
July 31, 2017
Study Completion (Actual)
January 30, 2019
Study Registration Dates
First Submitted
January 27, 2016
First Submitted That Met QC Criteria
January 28, 2016
First Posted (Estimate)
January 29, 2016
Study Record Updates
Last Update Posted (Actual)
September 28, 2022
Last Update Submitted That Met QC Criteria
September 26, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neuromoddevices
- TENT-A1 (Stage A1) (Other Identifier: Neuromod Devices Ltd.)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Mohab MohammedNot yet recruitingPulsatile Tinnitus (Diagnosis)
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
University of GuadalajaraHospital Civil de Guadalajara; Institute of Experimental and Clinical TherapeuticsRecruitingOxidative Stress | Tinnitus, Subjective | Tinnitus, Bilateral | Antioxidant Therapy | Psychiatric Drugs | Inflammatory Cytokines | SSRIMexico
-
University Hospital, BordeauxNot yet recruiting
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
Clinical Trials on PS1
-
University of MinnesotaNeuromod Devices Limited; Kent TaylorActive, not recruiting
-
Pharmasaga Co. Ltd.Recruiting
-
Neuromod Devices Ltd.Completed
-
Universidad Complutense de MadridHospital General Universitario Gregorio Marañon; Gerencia de Atención Primaria...Completed